MX2022014506A - Cisteina proteasa. - Google Patents

Cisteina proteasa.

Info

Publication number
MX2022014506A
MX2022014506A MX2022014506A MX2022014506A MX2022014506A MX 2022014506 A MX2022014506 A MX 2022014506A MX 2022014506 A MX2022014506 A MX 2022014506A MX 2022014506 A MX2022014506 A MX 2022014506A MX 2022014506 A MX2022014506 A MX 2022014506A
Authority
MX
Mexico
Prior art keywords
cysteine protease
igg
vivo
methods
polypeptide
Prior art date
Application number
MX2022014506A
Other languages
English (en)
Inventor
Christian Kjellman
Andersson Emma Nordahl
Kaisa Karhumaa
Karl Markus Roupé
Robert Bockermann
Sofia Järnum
Original Assignee
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Biopharma AB filed Critical Hansa Biopharma AB
Publication of MX2022014506A publication Critical patent/MX2022014506A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un polipéptido novedoso que exhibe la actividad de proteasa de cisteína IgG, y usos del mismo in vivo y ex vivo. Los usos del polipéptido incluyen métodos para la prevención o tratamiento de enfermedades y afecciones mediadas por IgG, y métodos para el análisis de IgG y generación in vitro de fragmentos F(ab')2.
MX2022014506A 2020-05-19 2021-05-18 Cisteina proteasa. MX2022014506A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2007431.6A GB202007431D0 (en) 2020-05-19 2020-05-19 Cysteine protease
PCT/EP2021/063131 WO2021233911A1 (en) 2020-05-19 2021-05-18 Cysteine protease

Publications (1)

Publication Number Publication Date
MX2022014506A true MX2022014506A (es) 2023-02-09

Family

ID=71135202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014506A MX2022014506A (es) 2020-05-19 2021-05-18 Cisteina proteasa.

Country Status (13)

Country Link
EP (1) EP4153737A1 (es)
JP (1) JP2023526849A (es)
KR (1) KR20230012550A (es)
CN (1) CN115698279A (es)
AU (1) AU2021275395A1 (es)
BR (1) BR112022023545A2 (es)
CA (1) CA3183617A1 (es)
CL (1) CL2022003205A1 (es)
CO (1) CO2022018347A2 (es)
GB (1) GB202007431D0 (es)
IL (1) IL298296A (es)
MX (1) MX2022014506A (es)
WO (1) WO2021233911A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
CN105770871A (zh) 2005-06-09 2016-07-20 汉莎医药有限公司 IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途
EP2190984B1 (en) 2007-09-14 2013-09-04 Genovis Ab Methods and kits for purification and detection of glycosylated IgG
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
WO2015184325A2 (en) * 2014-05-30 2015-12-03 New England Biolabs, Inc. Deglycosylation reagents and methods
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Also Published As

Publication number Publication date
EP4153737A1 (en) 2023-03-29
CL2022003205A1 (es) 2023-01-13
BR112022023545A2 (pt) 2023-01-17
AU2021275395A1 (en) 2022-12-15
CN115698279A (zh) 2023-02-03
IL298296A (en) 2023-01-01
GB202007431D0 (en) 2020-07-01
WO2021233911A1 (en) 2021-11-25
KR20230012550A (ko) 2023-01-26
JP2023526849A (ja) 2023-06-23
CO2022018347A2 (es) 2023-02-27
CA3183617A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
MX2022014506A (es) Cisteina proteasa.
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
MX2021000607A (es) Células t con receptor de antígeno quimérico derivadas de células madre pluripotentes inmunomodificadas.
HK1112367A1 (en) Survivin peptide vaccine
NO20063196L (no) Nye fusjonerte pyrrolokarbazoler
MX2012007416A (es) Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis.
HRP20050585A2 (en) Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
MX2023012981A (es) Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
SG149042A1 (en) Novel fused pyrrolocarbazoles
PH12021550789A1 (en) Disulfide bond stabilized polypeptide compositions and methods of use
MX2022014082A (es) Secuencias de interleucina (il-2) y usos de las mismas.
ZA202107428B (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
DE60319083D1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
MX2022004373A (es) Celulas madre modificadas y metodos de uso de las mismas.
SG162829A1 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
MX2023002350A (es) Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.
CA3156499A1 (en) CHINONE, HYDROCHINONE AND NAPHTOCHINONE ANALOGS OF VATIQUINONE FOR THE TREATMENT OF DISEASES WITH MITOCHONDRIAL DISORDERS
WO2006093858A3 (en) Method and composition for treating diabetes
TW200738752A (en) Modulation of MDL-1 activity for treatment of inflammatory disease
WO2006093881A3 (en) Method and composition for repairing epithelial and other cells and tissue
MX2021002936A (es) Uso de recambio plasmatico de bajo volumen para el tratamiento de la enfermedad de alzheimer en etapas temprana y moderada.
ZA202207539B (en) Composition and methods of manufacture
MX2022013770A (es) Relaxinas modificadas y metodos de uso de las mismas.